
    
      The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and
      immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior
      visilizumab study.

      PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
    
  